In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India

Abstract Background and Objectives The availability of a limited arsenal antibacterial agents effective against Burkholderia pseudomallei, the causative agent melioidosis, together with sporadic reports emergence resistance necessitates an evaluation in vitro activity new antimicrobials clinical B. pseudomallei isolates. Cefiderocol (CFDC), novel siderophore cephalosporin, ceftazidime-avibactam (CZA), β lactam combination agent, have shown promising results for treatment difficult-to-treat Gram-negative bacilli infections options. This study was conducted to determine CFDC CZA contemporary collection 60 Materials Methods Minimum inhibitory concentrations (MIC) were determined by broth microdilution E-test, respectively. performance disk diffusion also evaluated CFDC. Results All isolates susceptible MIC range 0.125 2 mg/L 0.19 1 mg/L, Zone diameters ranged from 31 40 mm. Conclusion exhibited excellent Further pharmacokinetic-pharmacodynamics studies trials are needed prove efficacy melioidosis.